Caspar Schmelzer
Skadden, Arps, Slate, Meagher & Flom LLP
Recognized since 2024
Frankfurt/Main, Germany
Practice Areas
Capital Markets Law
Caspar Schmelzer focuses primarily on capital markets transactions, advising clients in a variety of industries, including technology, automotive, consumer goods, financial and manufacturing. In recognition of his work, Mr. Schmelzer was named to Best Lawyers in Germany 2024 for Capital Markets Law.
Contact & Links
Location
- TaunusTurm
Taunustor 1
Frankfurt/Main 60310
Germany
Skadden, Arps, Slate, Meagher & Flom LLP Headquarters: New York, New York
16 The Best Lawyers in Germany™ awards
7 Best Lawyers: Ones to Watch in Germany™ awards
Recognized in The Best Lawyers in Germany™ 2026 for work in:
- Capital Markets Law
Transactions
Since joining Skadden, Mr. Schmelzer’s experience includes advising:
- Armira in its €30 million anchor investment as part of a €60 million private placement of new shares in tonies SE
- Medigene on its global cancer immunotherapy collaboration with BioNTech
- Silver Lake in its strategic partnership and investment in German publicly listed company Software AG via the purchase of €344 million aggregate principal amount of subordinated unsecured convertible notes. This is the first PIPE by any U.S. technology investment firm in a German public company
- Berenberg as sole global coordinator and joint bookrunner and Stifel as additional joint bookrunner in connection with a capital increase of Pacifico Renewables Yield AG
- SIGNA Sports United GmbH in connection with its US$3.3 billion initial public offering on the New York Stock Exchange as a result of the de-SPAC merger with Yucaipa Acquisition Corporation. The merger also included the acquisition of WiggleCRC Group
- Deutsche Bank, Goldman Sachs and J.P. Morgan as joint bookrunners in the €842 million private placement of ordinary bearer shares and listing on the Frankfurt Stock Exchange of ABOUT YOU Holding AG
- MorphoSys AG in its:
- cash capital increase with gross proceeds of approximately €102.7 million
- US$1.7 billion acquisition of Constellation Pharmaceuticals, Inc. and its related US$2 billion financing from Royalty Pharma plc
- U.S. IPO and dual listing of American depositary shares on Nasdaq
- issuance of a US$300 million development funding bond
Your browser is not fully compatible with our automatic printer friendly formatting.
Please use the print button to print this profile page.